Abstract
Purpose
Since the molecular mechanism of the cell cycle was established, various theoretical models of this process have been developed. A recent study revealed significant variability in cell cycle duration between mother and daughter cells, but this observation has not been incorporated into the theoretical models.
Methods
We used fluorescent ubiquitination-based cell cycle indicator (FUCCI) systems and live-monitored the heterogeneity of cell cycle progression within daughter cells, which accounts for dephasing synchrony. To incorporate the variable cell cycle durations into a model, we modified a two-ordinary differential equation (ODE) model based on reciprocal activation between CDK1 and APC.
Results
Our model reproduced the experimental population profile, in which cell cycle synchrony dephased due to variability. Based on this model, we determined parameters for CDK1 and APC in the cell cycle profile after treatment with antimitotic drugs and associated the parameters with the drugs’ mode of action as cell cycle inhibitors.
Conclusion
This suggests that this model is useful for determining the mode of action of unknown small molecules on the cell cycle.
Similar content being viewed by others
References
Alfieri R, Barberis M, Chiaradonna F, Gaglio D, Milanesi L, Vanoni M, et al. Towards a systems biology approach to mammalian cell cycle: modeling the entrance into S phase of quiescent fibroblasts after serum stimulation. BMC Bioinf. 2009;10(Suppl 12):S16.
Yao G, Lee TJ, Mori S, Nevins JR, You L. A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol. 2008;10:476–82.
Tsai TY, Choi YS, Ma W, Pomerening JR, Tang C, Ferrell JE Jr. Robust, tunable biological oscillations from interlinked positive and negative feedback loops. Science. 2008;321:126–9.
Steuer R. Effects of stochasticity in models of the cell cycle: from quantized cycle times to noise-induced oscillations. J Theor Biol. 2004;228:293–301.
Davidichand MI, Bornholdt S. Boolean network model predicts cell cycle sequence of fission yeast. PLoS One. 2008;3:e1672.
Mangla K, Dill DL, Horowitz MA. Timing robustness in the budding and fission yeast cell cycles. PLoS One. 2010;5:e8906.
Ferrell JE Jr, Tsai TY, Yang Q. Modeling the cell cycle: why do certain circuits oscillate? Cell. 2011;144:874–85.
Imamura TST. Quantitative imaging with Fucci and mathematics to uncover temporal dynamics of cell cycle progression. Develop Growth Differ. 2016;58:6–15.
Dowling MR, Kan A, Heinzel S, Zhou JH, Marchingo JM, Wellard CJ, et al. Stretched cell cycle model for proliferating lymphocytes. Proc Natl Acad Sci U S A. 2014;111:6377–82.
Shields R. Transition probability and the origin of variation in the cell cycle. Nature. 1977;267:704–7.
Engelberg J. The decay of synchronization of cell division. Exp Cell Res. 1964;36:647–62.
Bronk BV, Dienes GJ, Paskin A. The stochastic theory of cell proliferation. Biophys J. 1968;8:1353–98.
Andersonand EC, Peterson DF. Synchronized mammalian cells: an experimental test of a model for synchrony decay. Exp Cell Res. 1964;36:423–6.
Sandler O, Mizrahi SP, Weiss N, Agam O, Simon I, Balaban NQ. Lineage correlations of single cell division time as a probe of cell-cycle dynamics. Nature. 2015;519:468–71.
Bavetsiasand V, Linardopoulos S. Aurora kinase inhibitors: current status and outlook. Front Oncol. 2015;5:278.
Kim JJ, Gil NY, Zhang XH, Chun KH, Fang G, Kim J, et al. Sirt1 regulates microtubule dynamics through negative regulation of Plk1 in mitosis. J Cell Biochem. 2015;116:1888–97.
Jeong HC, Gil NY, Lee HS, Cho SJ, Kim K, Chun KH, et al. Timely degradation of Wip1 phosphatase by APC/C activator protein Cdh1 is necessary for normal mitotic progression. J Cell Biochem. 2015;116:1602–12.
Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H, et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell. 2008;132:487–98.
Press WH. Numerical recipes in fortran 77 : the art of scientific computing. Cambridge; New York: Cambridge University Press; 1996.
Goldbeter A. Computational approaches to cellular rhythms. Nature. 2002;420:238–45.
Pigolotti S, Krishna S, Jensen MH. Oscillation patterns in negative feedback loops. Proc Natl Acad Sci U S A. 2007;104:6533–7.
Sugimoto N, Tatsumi Y, Tsurumi T, Matsukage A, Kiyono T, Nishitani H, et al. Cdt1 phosphorylation by cyclin A-dependent kinases negatively regulates its function without affecting geminin binding. J Biol Chem. 2004;279:19691–7.
Rizzardi LF, Coleman KE, Varma D, Matson JP, Oh S, Cook JG. CDK1-dependent inhibition of the E3 ubiquitin ligase CRL4CDT2 ensures robust transition from S phase to mitosis. J Biol Chem. 2015;290:556–67.
Vodermaier HC. APC/C and SCF: controlling each other and the cell cycle. Curr Biol. 2004;14:R787–96.
Gavetand O, Pines J. Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis. Dev Cell. 2010;18:533–43.
Gorgun G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010;115:5202–13.
Seki A, Coppinger JA, Jang CY, Yates JR, Fang G. Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science. 2008;320:1655–8.
Dutertre S, Cazales M, Quaranta M, Froment C, Trabut V, Dozier C, et al. Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2-M transition. J Cell Sci. 2004;117:2523–31.
Asteriti IA, Di Cesare E, De Mattia F, Hilsenstein V, Neumann B, Cundari E, et al. The Aurora-A inhibitor MLN8237 affects multiple mitotic processes and induces dose-dependent mitotic abnormalities and aneuploidy. Oncotarget. 2014;5:6229–42.
Hofmeyrand JH, Cornish-Bowden A. The reversible Hill equation: how to incorporate cooperative enzymes into metabolic models. Comput Appl Biosci. 1997;13:377–85.
Goutelle S, Maurin M, Rougier F, Barbaut X, Bourguignon L, Ducher M, et al. The Hill equation: a review of its capabilities in pharmacological modelling. Fundam Clin Pharmacol. 2008;22:633–48.
Dominguez-Brauer C, Thu KL, Mason JM, Blaser H, Bray MR, Mak TW. Targeting mitosis in cancer: emerging strategies. Mol Cell. 2015;60:524–36.
Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14:130–46.
Hamiltonand E, Infante JR. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev. 2016;45:129–38.
Go Y-H, Lee H-J, Kong H-J, Jeong H-C, Lee DY, Hong S-K, et al. Screening of cytotoxic or cytostatic flavonoids with quantitative fluorescent ubiquitination-based cell cycle Indicator-based cell cycle assay. R Soc Open Sci. 2018;5:181303.
ACKNOWLEDGMENTS AND DISCLOSURES
This research was supported by Basic Science Research Program through the National Research Foundation of Korea(NRF) funded by the Ministry of Education(2018R1A6A1A03024940) and Research Resettlement Fund for the new faculty of Seoul National University (370C-20180036: C.HJ). The authors would also like to acknowledge the support from KISTI supercomputing center through the strategic support program for the supercomputing application research [Grant No. KSC-2015-C2-001]. The authors declare no conflict of interest.
Author information
Authors and Affiliations
Contributions
HJ.C and BJ.S conceived the overall study design and led the experiments. H.B, YH.G and T.K mainly conducted the experiments, data analysis, and critical discussion of the results. All authors contributed to manuscript writing and revising, and endorsed the final manuscript.
Corresponding authors
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Bae, H., Go, YH., Kwon, T. et al. A Theoretical Model for the Cell Cycle and Drug Induced Cell Cycle Arrest of FUCCI Systems with Cell-to-Cell Variation during Mitosis. Pharm Res 36, 57 (2019). https://doi.org/10.1007/s11095-019-2570-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11095-019-2570-2